CollabRx, Inc.

CIK:0000931059|SEC Filings

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Net revenues	$ 18,685,845	$ 13,036,172
Operating expenses:
Direct costs of revenues	7,574,548	6,767,921
General and administrative expenses	9,435,031	7,217,405
Depreciation and amortization	310,528	469,371
Total operating expenses	17,320,107	14,454,697
Income (loss) from continuing operations before other income (expense), income taxes and net loss attributable to noncontrolling interest	1,365,738	(1,418,525)
Other income (expense):
Other income, net	1,151,754	433,353
Gain from forgiveness of debt	200,000	334,819
Loss from legal settlements, net	(755,117)	(129,153)
Change in fair value of investment	(823,596)
Interest expense	(1,452,823)	(2,257,544)
Total other income (expense), net	(1,679,782)	(1,618,525)
Net loss from continuing operations before income taxes, including noncontrolling interest	(314,044)	(3,037,050)
Provision for income taxes	(239,834)	(312,849)
Net loss from continuing operations, including noncontrolling interest	(553,878)	(3,349,899)
(Loss) income from discontinued operations	(7,195,076)	56,844
Net loss, including noncontrolling interest	(7,748,954)	(3,293,055)
Net loss attributable to noncontrolling interest	19,793
Net loss attributable to Rennova	(7,729,161)	(3,293,055)
Deemed dividends		(330,876,369)
Net loss available to common stockholders	$ (7,729,161)	$ (334,169,424)
Net loss per share of common stock available to common stockholders- basic and diluted
Continuing operations - basic	$ (0.00)	$ (0.03)
Continuing operations - diluted	(0.00)	(0.03)
Discontinued operations - basic	(0.00)	0.00
Discontinued operations - diluted	(0.00)	0.00
Total basic	(0.00)	(0.03)
Total diluted	$ (0.00)	$ (0.03)
Weighted average number of shares of common stock outstanding during the period:
Basic	32,825,519,517	9,992,238,468
Diluted	32,825,519,517	9,992,238,468

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss from continuing operations, including noncontrolling interest	$ (553,878)	$ (3,349,899)
Adjustments to reconcile net loss to net cash provided by (used in) operations:
Depreciation and amortization	310,528	469,371
Non-cash interest income	(90,653)	(212,819)
Original issue discount on debt		50,000
Gain from forgiveness of debt	(200,000)	(334,819)
Net loss from legal settlements	755,117	129,153
Change in fair value of investment	823,596
Loss on disposal of equipment		1,650
Income from federal government provider relief funds	(285,572)	(595,692)
Changes in operating assets and liabilities:
Accounts receivable	23,549	(343,446)
Inventory	44,489	37,868
Prepaid expenses and other current assets	84,172	(93,486)
Security deposits	(10,039)	22,284
Change in right-of-use assets	215,062	247,018
Accounts payable	1,167,261	(6,704)
Accrued expenses	1,126,971	3,686,494
Change in right-of-use operating lease obligations	(215,062)	(247,018)
Income tax assets and liabilities	240,819	312,849
Net cash provided by (used in) operating activities of continuing operations	3,436,360	(227,196)
Net cash (used in) provided by operating activities of discontinued operations	(48,497)	8,848
Net cash provided by (used in) operating activities	3,387,863	(218,348)
Cash flows from investing activities:
Capital expenditures	(350,934)	(35,230)
Note receivable / receivable from related party	(1,180,401)	(869,961)
Net cash used in investing activities of continuing operations	(1,531,335)	(905,191)
Net cash from investing activities of discontinued operations
Net cash used in investing activities	(1,531,335)	(905,191)
Cash flows from financing activities:
Proceeds from issuance of related party loans	580,000	1,050,000
Payments on related party loans	(1,407,000)	(182,000)
Proceeds from issuance of debentures		500,000
Payments of debentures	(400,000)	(150,000)
Payments on notes payable	(1,079,983)	(1,415,610)
Receivables paid under accounts receivable sales agreements		(688,235)
Proceeds from federal government provider relief funds		284,339
Proceeds from issuances of Series P Preferred Stock		1,500,000
Cash paid for fractional shares in connection with reverse stock split		(9)
Net cash (used in) provided by financing activities of continuing operations	(2,306,983)	898,485
Net cash from financing activities of discontinued operations
Net cash (used in) provided by financing activities	(2,306,983)	898,485
Net change in cash	(450,455)	(225,054)
Cash at beginning of period	499,470	724,524
Cash at end of period	$ 49,015	$ 499,470

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash	$ 49,015	$ 499,470
Accounts receivable, net	3,087,420	3,110,969
Inventory	198,156	242,645
Prepaid expenses and other current assets	44,601	215,365
Income tax refunds receivable	837,460	837,460
Total current assets	6,944,959	6,363,162
Property and equipment, net	4,321,299	4,194,299
Intangible asset	259,443	259,443
Investment	8,192,476	9,016,072
Deposits	175,569	165,530
Right-of-use assets	359,194	574,256
Total assets	20,252,940	20,572,762
Current liabilities:
Accounts payable (includes related party amounts of $97,311 and $47,636, respectively)	12,371,566	11,204,305
Accrued expenses	15,399,268	19,384,803
Income taxes payable	1,589,244	1,348,425
Current portion of notes payable	1,026,758	2,917,390
Current portion of loan payable, related party	2,168,000	2,995,000
Current portion of debentures		8,622,240
Current portion of right-of-use operating lease obligations	183,345	215,063
Derivative liability	455,336	455,336
Current liabilities of discontinued operations	9,312,174	2,165,595
Total current liabilities	42,505,691	49,308,157
Long-term liabilities:
Accrued expenses	6,192,700
Debentures	8,222,240
Right-of-use operating lease obligations, net of current portion	175,849	359,193
Total liabilities	57,096,480	49,667,350
Commitments and contingencies
Stockholders’ deficit:
Common stock, $0.0001 par value, 250,000,000,000 shares authorized, 40,551,322,257 and 29,084,322,257 shares issued and outstanding, respectively	4,055,132	2,908,432
Additional paid-in-capital	1,670,425,144	1,671,571,834
Accumulated deficit	(1,711,306,941)	(1,703,577,780)
Total Rennova’s stockholders’ deficit	(36,823,749)	(29,094,588)
Noncontrolling interest	(19,791)
Total stockholders’ deficit	(36,843,540)	(29,094,588)
Total liabilities and stockholders’ deficit	20,252,940	20,572,762
Series H Preferred Stock [Member]
Stockholders’ deficit:
Preferred stock, value
Series L Preferred Stock [Member]
Stockholders’ deficit:
Preferred stock, value	2,500	2,500
Series M Preferred Stock [Member]
Stockholders’ deficit:
Preferred stock, value	208	208
Series N Preferred Stock [Member]
Stockholders’ deficit:
Preferred stock, value	24	29
Series O Preferred Stock [Member]
Stockholders’ deficit:
Preferred stock, value	82	87
Series P Preferred Stock [Member]
Stockholders’ deficit:
Preferred stock, value	102	102
Related Party [Member]
Current assets:
Note receivable from related party	2,728,307	1,457,253
Current liabilities:
Current portion of loan payable, related party	$ 2,168,000	$ 2,995,000